Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Cash from Operations (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Cash from Operations for 2 consecutive years, with 6405352.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 90.74% to 6405352.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 2308850.0, a N/A change, with the full-year FY2025 number at 100000.0, up 100.68% from a year prior.
  • Cash from Operations was 6405352.0 for Q4 2025 at Neuphoria Therapeutics, down from 3794648.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 11453452.0 in Q1 2025 to a low of 6405352.0 in Q4 2025.